| Cervical Carcinoma altered in cohorts of …ALTERED_INderived200 of 354show all (up to 200) |
|---|
| ← altered in cohorts of | PIK3CA 248 / 306 cases (81 %) · ssm · TCGA-CESC · largest of 6 cohorts | — | — | Cervical Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | SI 228 / 306 cases (75 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TNIK 228 / 306 cases (75 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | BCHE 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN16 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC3B 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A14 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATA16 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TBL1XR1 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBBX 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCC5 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTRT3 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A5 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL6 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN11 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LPP 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC31 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC34 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYNN 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | P3H2 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PEX5L 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLD1 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRKCI 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC62 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SKIL 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TP63 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR49 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCF3 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL6A 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A4 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ECT2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GHSR 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL1RAP 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | IQCG 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRIQ4 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MB21D2 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MCF2L2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MECOM 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC4 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 5 cohorts | — | — | Cervical Carcinoma | 5 | Observed | gdc | graph → |
| ← altered in cohorts of | NCEH1 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OPA1 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHC3 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SAMD7 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC2A2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLITRK3 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM207 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFSF10 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS8 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | AP2M1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC39 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRD 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DGKG 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF2B5 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF5A2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGF12 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLIM4 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR160 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HRG 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNMB2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LIPH 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MFN1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPL47 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGZ 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PLAAT1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22L1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RUBCN 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINI2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SOX2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZMAT3 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF639 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADIPOQ 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC50 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DLG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1AKMT4-ECE2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EHHADH 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GMNC 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3C 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3D 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3E 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL24 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL6 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRCH3 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LSG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MCCC1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MELTF 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NAALADL2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PYDC2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINI1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM212 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM44 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TPRG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | UBXN7 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | USP13 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YEATS2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ARID1A 136 / 247 cases (55 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CEP19 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC20 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCBP2 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCBP2AS2 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NRROS 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAK2 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGX 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SENP5 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BDH1 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO45 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FYTTD1 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCYT1A 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF168 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC51A 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMCO1 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TCTEX1D2 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TFRC 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TM4SF19 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TM4SF19-TCTEX1D2 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR53 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZDHHC19 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LMLN 95 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL35A 95 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNK2 95 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACAP2 92 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP11B 92 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM131A 92 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NLGN1 92 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APOD 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECE2 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAP3K13 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OSTN 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPP1R2 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SENP2 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM41A 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRA2B 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UTS2B 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | XXYLT1 91 / 208 cases (44 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALG3 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C3orf70 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CPN2 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DVL3 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HES1 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMP3 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC15 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAGEF1 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PARL 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POLR2H 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VWA5B2 90 / 208 cases (43 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIK3R1 91 / 247 cases (37 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TTN 91 / 291 cases (31 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Cervical Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CTNNB1 71 / 247 cases (29 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KRAS 67 / 247 cases (27 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2B 62 / 247 cases (25 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | INPPL1 61 / 247 cases (25 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CTCF 56 / 247 cases (23 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZFHX3 54 / 247 cases (22 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FSIP2 47 / 247 cases (19 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2C 54 / 291 cases (19 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Cervical Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR1 45 / 247 cases (18 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZFHX4 45 / 247 cases (18 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | JAK1 43 / 247 cases (17 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DNAH5 42 / 247 cases (17 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CHD4 41 / 247 cases (17 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FAT3 41 / 247 cases (17 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | HERC2 41 / 247 cases (17 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC16 48 / 291 cases (16 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Cervical Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DNAH17 40 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRTM3 40 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR3 40 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FAT4 39 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FGFR2 39 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LYST 39 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MED12 39 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | NSD1 39 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PLEC 39 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF469 39 / 247 cases (16 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CACNA1A 38 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SETD1B 38 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | USP9X 38 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BLTP1 37 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPEG 37 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CACNA1E 36 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DOCK3 36 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DYNC1H1 36 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FAT2 36 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LAMA2 36 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC12 36 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MYO15A 36 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TENM3 36 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANKRD11 35 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PKD1 35 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SRCAP 35 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TNRC18 35 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2D 41 / 291 cases (14 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Cervical Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | AHNAK 34 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BAHCC1 34 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BCOR 34 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DNAH1 34 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RGS12 34 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | STARD9 34 / 247 cases (14 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ABCA12 33 / 247 cases (13 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |